Dr. Can Cui is a partner in Goodwin’s Life Sciences group. His practice focuses on technology transactions and investment in the life sciences industry, especially those transactions related to China, including cross-border technology licensing and acquisition, collaboration and strategic partnership, joint venture (JV), and other forms of investment.

Dr. Cui has extensive experience representing both licensors and licensees in U.S.-China life sciences licensing transactions. In private equity and venture capital transactions, he regularly represents institutional and individual investors, established life sciences companies and startups in intellectual property (IP) due diligence and the negotiation and drafting of related investment documentation. He also advises clients on IP aspects of mergers and acquisitions.

Dr. Cui has deep knowledge of China’s increasingly complex regulatory landscape, including not only the IP laws, but also regulations governing cross-border transactions, such as technology import and export regulations and regulations of human genetic resources. He also has rich experiences in corporate matters, patent prosecution and IP dispute resolution, which, together with his scientific background, make him a go-to person for advice in various legal matters life sciences companies may have.

In addition to his legal services to the life sciences industry, Dr. Cui is also an active participant in a wide variety of pro bono matters. He has been a recipient of the California Lawyers Association’s Wiley W. Manuel Certificate for Pro Bono Legal Services in recent years.




除了为生命科学行业提供法律服务外,崔博士还积极参与各种公益法律事务。崔博士近年来屡次获得加州律师协会颁发的Wiley W. Manuel公益法律服务证书
Areas of Practice
Domaines D’Expertise





Dr. Cui has advised the following companies, among others, in the life sciences industry in the following transactions and matters, among others:

  • ACROBiosystems Inc.: various licensing, collaboration, sales, distribution, consulting and investment transactions, and IP matters;*

  • A publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies: various collaboration, licensing, and services transactions, and employee IP matters;*

  • A biotechnology company that leverages revolutionary drug targets to develop and commercialize transformational therapies in autoimmune diseases, cancers and transplantations: various services, manufacturing, and consulting agreements;*

  • A Shanghai-based biopharma company developing next generation anti-cancer therapies: various licensing and co-development transactions, and IP due diligence matters;*

  • A clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system: various licensing, collaboration, and clinical services transactions, and China IP, JV and regulatory matters;*

  • Evive Biotechnology (Shanghai) Ltd.: various licensing and collaboration transactions, including with the Memorial Sloan-Kettering Cancer Center, and patent applications;

  • GenScript Biotech Corporation and its clinical-stage oncology biotech subsidiary, Legend Biotech Corporation:

    • licensing transactions, including with Amgen and Noile-Immune Biotech, Inc., respectively;*

    • technology services transactions;*

    • strategic collaborations, including with REMD Biotherapeutics Inc.;*

    • various strategic partnership transactions;*

    • acquisition of CustomArray, Inc.;* and

    • Chinese IP law and compliance matters;*

  • HebeCell Corp: various licensing and collaboration transactions;*

  • Helio Health Inc.: various licensing transactions, including with universities, and patent applications;*

  • Livzon Pharmaceutical Group Inc.:

    • $33 million Series B financing of Elicio Therapeutics;*

    • $47 million Series B financing of Carisma Therapeutics;* and

    • U.S. regulatory advice;*

  • Qilu Pharmaceutical Co., Ltd.: various collaboration and licensing transactions;

  • T-Cure Bioscience, Inc.:

    • license agreement with Immunotech Biopharm Ltd;* and

    • clinical research agreement with Rutgers, The State University of New Jersey;*

  • A global leader of 3D printing pharmaceuticals: various collaboration and services transactions, and employee and consultant IP matters;

  • Vazyme Biotech Co., Ltd: IP dispute and product distribution matters;* and

  • Warburg Pincus Asia LLC:

    • freedom-to-operate and other China IP due diligence matters;*

    • 1.2 billion Series B financing of Haihe Pharmaceutical;* and

    • $123 million Series D financing of Abbisko Therapeutics.*
*Denotes experience prior to joining Goodwin.


  • ACROBiosystems公司:各种许可、合作、销售、分销、咨询和投资交易,以及知识产权事宜*

  • 一家致力于转化基于抗体的新型癌症免疫疗法的发现和开发的上市全球性临床阶段生物制药公司:各种合作、许可和服务交易,以及员工知识产权事宜*

  • 一家利用革命性的药物靶点开发和商业化自身免疫疾病、癌症和移植的转化疗法的生物技术公司:各种服务、制造和咨询协议*

  • 一家开发下一代抗癌疗法的上海生物制药公司:各种许可和合作开发交易,以及知识产权尽职调查事项*

  • 一家以通过开发利用免疫系统进化能力的新型T细胞疗法来治疗癌症为目标的临床阶段生物制药公司:各种许可、合作和临床服务交易,以及中国知识产权、合资企业和监管事项*

  • 亿一生物医药开发(上海)有限公司:各种许可和合作交易,包括与Memorial Sloan-Kettering Cancer Center的合作,以及专利申请

  • 金斯瑞生物科技股份有限公司及其临床阶段肿瘤生物技术的子公司南京传奇生物科技有限公司:

    • 别与安进和Noile-Immune Biotech公司的许可交易*

    • 术服务交易*

    • 战略合作事宜,包括与REMD Biotherapeutics公司的合作*

    • 各种战略伙伴交易*

    • CustomArray公司*以及

    • 中国知识产权法和合规事项*

  • HebeCell公司:各种许可和合作交易*

  • Helio Health公司:包括与大学之间的各种许可交易和专利申请*

  • 丽珠医药集团股份有限公司:

    • Elicio Therapeutics3300万美元B轮融资*

    • Carisma Therapeutics4700万美元B轮融资*以及

    • 美国监管咨询*

  • 齐鲁制药集团:各种合作及许可交易

  • T-Cure Bioscience公司:

    • Immunotech Biopharm公司的许可协议*以及

    • 与罗格斯,新泽西州立大学的临床研究协议*

  • 一家3D打印药物的全球领导者:各种合作和服务交易,以及员工和顾问知识产权事宜
  • 南京诺唯赞生物科技股份有限公司:知识产权纠纷和产品分销事宜*

  • 华平投资:

    • 自由使用权和其他中国知识产权尽职调查事项*

    • 海和药物的12亿元人民币B轮融资*以及

    • 和誉医药的1.23亿美元D轮融资*


Professional Experience

Prior to joining Goodwin, Dr. Cui was an associate in the IP and Technology Transactions Groups of Morrison & Foerster LLP (“MoFo”), where he was a key member of the firm’s China Life Sciences practice. During his four-year residency in the firm’s Hong Kong office, he managed, in addition to cross-border licensing and investment transactions, patent dispute matters in China on behalf of MoFo’s U.S. clients, and gained extensive experience in IP dispute resolution in China. During his subsequent five-year residency in MoFo’s San Francisco office, he continued to represent clients in both China and the U.S. in their cross-border technology transactions and investments, and played a leading role in those transactions in the life sciences industry.

While working in MoFo’s Hong Kong office, Dr. Cui was an adjunct faculty member at The Chinese University of Hong Kong (CUHK). During his three-year tenure at CUHK Faculty of Law, he taught the Principles of Intellectual Property course, and established CUHK’s Chinese IP Law course.

Prior to and while attending law school, Dr. Cui worked as a U.S. patent agent in the Boston and New York offices of Ropes & Gray LLP, where he was a member of the Fish & Neave IP Group.

As a graduate student at Harvard, Dr. Cui conceived, established, and maintained a major long-term collaborative project among Harvard Medical School, the University of California, San Diego, and the Chinese Academy of Sciences. His identification of a viral microRNA was featured in the “Spotlight” section of Journal of Virology as an article of significant interest selected by the editors.



在上法学院之前和期间,崔博士作为Fish & Neave识产权组的成员在瑞格律师事务所的波士顿和纽约办事处担任美国专利代理人。

为哈佛大学的研究生,他构思、建立并维系了一项由哈佛医学院、加州大学圣地亚哥分校和中国科学院共同参与的重要长期合作项目。他的关于病毒微小RNA 的突破性发现发表在《病毒学学报》(Journal of Virology)的焦点Spotlight专栏,并被编辑特选为极具影响力的文章
Professional Activities

Dr. Cui is a member of American Bar Association, New York State Bar Association, California Lawyers Association, Bar Association of San Francisco, and San Francisco Bay Area Intellectual Property Inn of Court.

Dr. Cui is a frequent guest lecturer and panelist at top universities and law schools in the United States and in China on U.S. patent law, cross-border technology licensing, and IP protection in the life sciences industry.




Dr. Cui is recognized by Berkeley Center for Law & Technology as one of the “leading practitioners in biotech and life sciences.”


崔博士被伯克利法律和技术中心(Berkeley Center for Law & Technology认可为生物技术和生命科学领域的领先执业者之一。

In The News









J.D., 2012
New York University School of Law
(magna cum laude; The Order of the Coif; Weinfeld Fellow; Walter J. Derenberg Prize, NYU Law’s only Convocation Award in IP Law; NYU Journal of Law & Business: Staff Editor (2010-11); Board Member and Senior Articles Editor (2011-12))
Ph.D., Biological Chemistry & Molecular Pharmacology, 2007
Harvard University
B.Sc., Biotechnology, 2000
Peking University
(summa cum laude; Valedictorian; Shuping Scholar; High Distinction Honor)


法学博士, 2012
(极优等毕业生magna cum laude;美国杰出法律学会白帽协会(The Order of the Coif)的荣誉会员;Weinfeld Fellow;纽约大学法学院唯一知识产权法毕业生荣誉奖Walter J. Derenberg奖得主;《纽约大学法律与商业学报》(NYU Journal of Law & Business)的论文编辑(2010-11)、资深编辑及编委会委员(2011-12))
生物化学与分子药理学博士, 2007
生物技术学士, 2000
(最优等毕业生summa cum laude;毕业生代表;叔苹奖学金; 毕业生优秀论文)



New York



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique